Three senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to disclose what he and President Donald Trump discussed with drugmakers during closed-door conversations.

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer continued to warn users to not trust billionaires. His ...